Public Employees Retirement Association of Colorado reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 2.5% during the second quarter, Holdings Channel.com reports. The institutional investor owned 201,032 shares of the biopharmaceutical company’s stock after selling 5,179 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Gilead Sciences were worth $15,494,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Altshuler Shaham Ltd grew its position in shares of Gilead Sciences by 7.0% during the 4th quarter. Altshuler Shaham Ltd now owns 1,856 shares of the biopharmaceutical company’s stock worth $159,000 after buying an additional 121 shares in the last quarter. Intercontinental Wealth Advisors LLC increased its position in Gilead Sciences by 2.4% during the 2nd quarter. Intercontinental Wealth Advisors LLC now owns 5,458 shares of the biopharmaceutical company’s stock valued at $421,000 after purchasing an additional 126 shares during the period. Baker Tilly Wealth Management LLC raised its holdings in shares of Gilead Sciences by 2.3% in the 2nd quarter. Baker Tilly Wealth Management LLC now owns 5,694 shares of the biopharmaceutical company’s stock valued at $439,000 after purchasing an additional 128 shares in the last quarter. Pinkerton Retirement Specialists LLC boosted its stake in shares of Gilead Sciences by 2.8% during the first quarter. Pinkerton Retirement Specialists LLC now owns 4,703 shares of the biopharmaceutical company’s stock valued at $390,000 after purchasing an additional 129 shares in the last quarter. Finally, DGS Capital Management LLC increased its holdings in Gilead Sciences by 2.0% during the first quarter. DGS Capital Management LLC now owns 6,570 shares of the biopharmaceutical company’s stock valued at $545,000 after buying an additional 131 shares during the period. 82.33% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
Several analysts have issued reports on GILD shares. Cantor Fitzgerald dropped their target price on Gilead Sciences from $85.00 to $80.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 19th. Deutsche Bank Aktiengesellschaft started coverage on Gilead Sciences in a research report on Thursday, November 9th. They set a “hold” rating and a $75.00 price objective on the stock. Bank of America upgraded shares of Gilead Sciences from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $88.00 to $95.00 in a report on Friday, September 8th. Leerink Partnrs restated a “market perform” rating on shares of Gilead Sciences in a report on Wednesday, October 11th. Finally, BMO Capital Markets decreased their target price on shares of Gilead Sciences from $100.00 to $95.00 in a research report on Tuesday, July 18th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $88.61.
In related news, CFO Andrew D. Dickinson sold 5,000 shares of the firm’s stock in a transaction on Tuesday, October 17th. The shares were sold at an average price of $80.00, for a total transaction of $400,000.00. Following the sale, the chief financial officer now owns 104,003 shares in the company, valued at $8,320,240. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, CFO Andrew D. Dickinson sold 5,000 shares of the company’s stock in a transaction dated Tuesday, October 17th. The stock was sold at an average price of $80.00, for a total value of $400,000.00. Following the completion of the transaction, the chief financial officer now owns 104,003 shares of the company’s stock, valued at approximately $8,320,240. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Merdad Parsey sold 1,501 shares of the firm’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $76.99, for a total value of $115,561.99. Following the completion of the sale, the insider now directly owns 70,130 shares in the company, valued at $5,399,308.70. The disclosure for this sale can be found here. Insiders own 0.21% of the company’s stock.
Gilead Sciences Price Performance
Shares of NASDAQ:GILD opened at $74.93 on Tuesday. The company has a current ratio of 1.34, a quick ratio of 1.20 and a debt-to-equity ratio of 1.08. Gilead Sciences, Inc. has a twelve month low of $72.87 and a twelve month high of $89.74. The company’s 50 day moving average is $76.82 and its 200 day moving average is $77.43. The company has a market cap of $93.37 billion, a PE ratio of 16.08, a price-to-earnings-growth ratio of 0.86 and a beta of 0.32.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported $2.29 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.38. Gilead Sciences had a return on equity of 39.30% and a net margin of 21.45%. The business had revenue of $7.05 billion during the quarter, compared to analyst estimates of $6.81 billion. During the same quarter last year, the business posted $1.90 EPS. The company’s revenue was up .1% on a year-over-year basis. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post 6.73 EPS for the current year.
Gilead Sciences Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be given a $0.75 dividend. The ex-dividend date is Thursday, December 14th. This represents a $3.00 annualized dividend and a yield of 4.00%. Gilead Sciences’s dividend payout ratio is presently 64.38%.
Gilead Sciences Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.
- Five stocks we like better than Gilead Sciences
- Space Investment: How to Invest in Space Exploration
- This analyst says Archer Aviation may double, is it time to buy?
- Learn Technical Analysis Skills to Master the Stock Market
- Utilities may be the best play for a turbulent holiday quarter
- What is a Death Cross in Stocks?
- Capitalizing on value: 3 undervalued stocks ready for resurgence
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.